BioNTech and partner DualityBio advanced their B7‑H3–targeting antibody‑drug conjugate into a Phase III trial for metastatic castration‑resistant prostate cancer (mCRPC), moving faster than a competing Merck‑Daiichi program by planning a study with roughly half the patient count. The decision follows encouraging Phase I/II data showing activity in the target population. The partners said the streamlined Phase III design aims to validate efficacy while controlling costs and timelines. The program underscores continued industry interest in ADCs directed at solid tumors and in B7‑H3 as a target across multiple malignancies. If successful, the BioNTech/DualityBio ADC could claim a differentiated development pathway against larger, resource‑intensive rivals in the prostate cancer space.